Mosby's 2014 Nursing Drug Reference (429 page)

BOOK: Mosby's 2014 Nursing Drug Reference
9.5Mb size Format: txt, pdf, ePub
Recent FDA drug approvals

Appendix A
Selected new drugs
alogliptin

(al′oh-glip′tin)

Nesina

Func. class.:
Antidiabetic

Chem. class.:
Dipeptidyl peptidase-4 (DPP-4) inhibitor

ACTION:

A dipeptidyl-peptidase-IV (DDP-IV) inhibitor for the treatment of type 2 diabetes mellitus (monotherapy or in combination with other antidiabetic agents), potentiates the effects of the incretin hormones by inhibiting their breakdown by DDP-IV

USES:

Type 2 diabetes mellitus (T2DM)

CONTRAINDICATIONS:

Hypersensitivity

Precautions:
Pregnancy (B), breastfeeding, hepatic disease, burns, ketoacidosis, diarrhea, fever, GI obstruction, hyper/hypoglycemia, hyper/hypothyroidism, type 1 diabetes, hypercortisolism, children, ileus, malnutrition, pancreatitis, surgery, trauma, vomiting, kidney disease, adrenal insufficiency

 

Black Box Warning:

Angioedema

DOSAGE AND ROUTES
Calculator

• Adult:
PO
25 mg/day; when used in combination, a lower dose of the other antidiabetic may be needed

Renal dose

• Adult:
PO
CCr 30–59 ml/min: 12.5 mg q day; CCr <30 ml/min: 6.25 mg q day; intermittent hemodialysis: 6.25 mg q day; give without regard to the timing of hemodialysis

Available forms:
Tab 6.25, 12.5, 25

Administer:

• 
Without regard to food

SIDE EFFECTS

CNS:
Headache

GI:
Pancreatitis

META:
Hypoglycemia

RESP:
Upper respiratory infection, nasopharyngitis

SYST:
Rash, hypersensitivity,
angioedema, Stevens–Johnson syndrome

PHARMACOKINETICS

20% protein binding, excreted unchanged (urine), peak 1-2 hr, effect decreased in liver disease and increased in kidney disease

INTERACTIONS
Drug/Lab Test

Increase:
LFTs

NURSING CONSIDERATIONS
Assess:

• 
Diabetes:
monitor blood glucose, glycosylated hemoglobin A1c (A1c), LFTs, serum creatinine/BUN

 
Pancreatitis:
Can occur during use

 
Hypersensitivity reactions:
angioedema, Stevens–Johnson syndrome; product should be discontinued

Evaluate:

• 
Positive therapeutic response: Decrease in polyuria, polydipsia, polyphagia, clear sensorium, absence of dizziness, improvement in A1c, daily blood glucose monitoring

Teach patient/family:

• 
That diabetes is a life-long condition, product does not cure disease

• 
That all food in diet plan must be eaten to prevent hypoglycemia; to continue with weight control, dietary medical nutrition therapy, physical activity, hygiene

• 
To carry emergency ID with prescriber, medications, and condition listed

• 
To test blood glucose using a blood glucose meter

Canada only   Side effects:
italics
= common;
bold
= life-threatening   
Nurse Alert

bosutinib

(boe-sue′ti-nib)

Bosulif

Func. class.:
Antineoplastic biologic response modifiers

Chem. class.:
Signal transduction inhibitors (STIs), tyrosine kinase inhibitor

ACTION:

Inhibits bcr-abl tyrosine kinase created in patients with chronic myeloid leukemia (CML)

USES:

Treatment of CML; Philadelphia-chromosome–positive patients in blast-cell crisis

CONTRAINDICATIONS:

Pregnancy (D), hypersensitivity

Precautions:
Breastfeeding, children, diarrhea, geriatric patients, hepatic disease, bone marrow suppression, infection, thrombocytopenia, neutropenia, immunosuppression

DOSAGE AND ROUTES
Calculator

• Adult:
PO
500 mg daily with food, may increase to 600 mg/day in those who have not developed grade 3 toxicity or in patients who do not reach complete hematological response by wk 8 or complete cytogenic response (CCyR) by wk 12

Hepatic dosage

• Adult:
PO
Any baseline hepatic impairment: Start at 200 mg/day; liver transaminase >5 × ULN, hold dose until levels are ≤2.5 × ULN, then resume at 400 mg/day; liver transaminase level ≥3 × ULN and bilirubin >2 × ULN and alk phos <2 × ULN, discontinue

Dosage adjustments for treatment-related toxicity
Hematologic toxicity:

 
ANC
<
1000
×
10
6
/L or platelet count
<
50,000
×
10
6
/L:
hold dose until ANC is ≥1000 × 10
6
/L and platelets are ≥50,000 × 10
6
/L; if recovery within 2 wk, resume therapy at the same dosage; if blood counts remain low after 2 wk, upon recovery, resume at 100 mg/day less than the previous dosage

Diarrhea:

 
Grade 3 or 4 diarrhea (

7 stools/day compared with baseline):
hold therapy until recovery to grade 1 toxicity or lower; resume therapy at 400 mg/day

Other nonhematologic toxicity:

 
Significant or moderate or severe toxicity:
hold therapy until toxicity resolves; resume therapy at 400 mg/day

Available forms:
Tabs 100, 500 mg

Administer:
PO route

• 
Give with food; swallow whole

• 
If dose is missed, take within 12 hr of missed dose; if >12 hr have passed, skip dose

• 
Follow cytotoxic handling procedures

SIDE EFFECTS

CNS:
Headache, dizziness

GI:
Nausea, vomiting, anorexia, abdominal pain, diarrhea

HEMA:
Neutropenia, thrombocytopenia, bleeding

INTEG:
Rash, pruritus

MS:
Arthralgia, myalgia

RESP:
Cough, dyspnea, pleural effusion, edema

OTHER:
Elevated LFTs

PHARMACOKINETICS

Protein binding 96%; metabolized by CYP3A4; half-life 22.5 hr

INTERACTIONS

Increase:
bosutinib concentrations—CYP3A4 inhibitors (ketoconazole, itraconazole, erythromycin, clarithromycin)

Increase:
plasma concentrations of simvastatin, calcium channel blockers, ergots

Decrease:
bosutinib concentrations—CYP3A4 inducers (dexamethasone, phenytoin, carBAMazepine, rifampin, PHENobarbital), antacids, proton-pump inhibitors

Drug/Food

Increase:
increase bosutinib effect—grapefruit juice; avoid use while taking product

Drug/Herb

Decrease:
bosutinib concentration—St. John’s wort

Nursing considerations
Assess:

 
Myelosuppression: anemia, thrombocytopenia, neutropenia; obtain a CBC weekly × 1 mo, then monthly as needed

• 
LFTs every mo × 3 mo, then as clinically indicated

Evaluate:

• 
Therapeutic response: decrease in leukemic cells or size of tumor

Teach patient/family:

• 
To report adverse reactions immediately, bleeding

• 
About reason for treatment, expected results

• 
To use effective contraception during treatment and up to 30 days after discontinuing treatment

Other books

Crusader Captive by Merline Lovelace
Luca's Bad Girl by Amy Andrews
Someone Elses Daughter by Jack Norman
Atom by Steve Aylett
Wicked End by Bella Jeanisse
Hackers on Steroids by Oisín Sweeney
Humans by Robert J. Sawyer